133550-34-2 Usage
Description
TYRPHOSTIN B46 is a tyrphostin inhibitor that specifically targets the EGF receptor kinase activity. It is a synthetic compound derived from naturally occurring tyrphostins, which are protein tyrosine kinase inhibitors. TYRPHOSTIN B46 selectively inhibits the EGF receptor (EGFR) over other related receptors, such as ErbB2, making it a valuable tool in studying the role of EGFR in various biological processes.
Uses
Used in Pharmaceutical Industry:
TYRPHOSTIN B46 is used as a research tool for studying the role of EGFR in cell proliferation, differentiation, and survival. It helps researchers understand the molecular mechanisms underlying the regulation of these processes by EGFR, which can lead to the development of novel therapeutic strategies for various diseases.
Used in Cancer Research:
TYRPHOSTIN B46 is used as an inhibitor of EGFR in cancer research, particularly in the study of tumors that overexpress this receptor. By inhibiting EGFR activity, TYRPHOSTIN B46 can help investigate the role of this receptor in tumor growth, invasion, and metastasis, as well as its potential as a therapeutic target for cancer treatment.
Used in Drug Discovery:
TYRPHOSTIN B46 is used as a lead compound in the development of new drugs targeting EGFR-mediated signaling pathways. Its selective inhibition of EGFR makes it a valuable starting point for the design and synthesis of more potent and specific EGFR inhibitors, which can be used as targeted therapies for various cancers and other diseases.
Used in Cell Biology Research:
TYRPHOSTIN B46 is used as a reagent in cell biology research to study the effects of EGFR inhibition on cellular processes such as migration, adhesion, and apoptosis. This can provide insights into the role of EGFR in normal cellular functions and its dysregulation in disease states.
Overall, TYRPHOSTIN B46 is a versatile and valuable compound in various fields of research and drug development, particularly in the study and treatment of diseases involving the EGF receptor and its signaling pathways.
Biological Activity
Potent epidermal growth factor receptor (EGFR) kinase inhibitor (IC 50 = 0.7 μ M) that displays 50-fold and >140-fold selectivity over ErbB2 and insulin receptor kinase respectively. Induce G 1 growth arrest selectively in transformed cells (IC 50 values are 6.4 and 9.4 μ M in HPV16-immortalized and normal keratinocytes respectively).
references
[1]. ben-bassat h, rosenbaum-mitrani s, hartzstark z, et al. inhibitors of epidermal growth factor receptor kinase and of cyclin-dependent kinase 2 activation induce growth arrest, differentiation, and apoptosis of human papilloma virus 16-immortalized human keratinocytes. cancer res, 1997, 57(17): 3741-3750.[2]. kleinberger-doron n, shelah n, capone r, et al. inhibition of cdk2 activation by selected tyrphostins causes cell cycle arrest at late g1 and s phase. exp cell res, 1998, 241(2): 340-351.[3]. sion-vardy n, vardy d, rodeck u, et al. antiproliferative effects of tyrosine kinase inhibitors (tyrphostins) on human bladder and renal carcinoma cells. j surg res, 1995, 59(6): 675-680. [4]. seri i, aflalo e, gazit a, et al. tyrphostin ag-555 inhibits early and late stages of moloney murine leukemia virus replication cycle. int j oncol, 1997, 10(6): 1185-1189.
Check Digit Verification of cas no
The CAS Registry Mumber 133550-34-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,3,5,5 and 0 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 133550-34:
(8*1)+(7*3)+(6*3)+(5*5)+(4*5)+(3*0)+(2*3)+(1*4)=102
102 % 10 = 2
So 133550-34-2 is a valid CAS Registry Number.
InChI:InChI=1/C19H18N2O3/c20-13-16(11-15-8-9-17(22)18(23)12-15)19(24)21-10-4-7-14-5-2-1-3-6-14/h1-3,5-6,8-9,11-12,22-23H,4,7,10H2,(H,21,24)/b16-11+
133550-34-2Relevant articles and documents
Tyrphostins. 2. Heterocyclic and α-Substituted Benzylidenemalonitrile Tyrphostins as Potent Inhibitors of EGF Receptor and ErbB2/neu Tyrosine Kinases
Gazit, Aviv,Osherov, Nir,Posner, Israel,Yaish, Pnina,Poradosu, Enrique,et al.
, p. 1896 - 1907 (2007/10/02)
We have previously described a novel series of low molecular weight protein tyrosine kinase inhibitors which we named tyrphostins.The characteristic active pharmacophore of these compounds was the hydroxy-cis-benzylidenemalonitrile moiety.In this article we describe three novel groups of tyrphostins: (i) one group has the phenolic moiety of the cis-benzylidenemalononitrile replaced either with other substituted benzenes or with heteroaromatic rings, (ii) another is a series of conformationally constrained derivatives of hydroxy-cis-benzylidenemalononitriles in which the malononitrile moiety is fixed relative to the aromatic ring, and (iii) two groups of compounds in which the position trans to the benzenemalononitrile has been substituted by ketones and amides.Among the novel tyrphostins examined we found inhibitors which discriminate between the highly homologous EGF receptor kinase (HER1) and ErbB2/neu kinase (HER2).These findings may lead to selective tyrosine kinase blockers for the treatment of diseases in which ErbB2/neu is involved.
